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http://www.biomedcentral.com/1471-2474/15/166RESEARCH ARTICLE Open AccessRegulation of ubiquitin-proteasome and
autophagy pathways after acute LPS and
epoxomicin administration in mice
Cécile Jamart1, Aldrin V Gomes2, Shannamar Dewey2, Louise Deldicque3, Jean-Marc Raymackers1
and Marc Francaux1*Abstract
Background: The ubiquitin-proteasome pathway (UPP) is a major protein degradation pathway that is activated
during sepsis and has been proposed as a therapeutic target for preventing skeletal muscle loss due to cachexia.
Although several studies have investigated the modulation of proteasome activity in response to LPS administration,
none have characterized the overall UPP response to LPS administration in the fate of proteasome inhibition.
Methods: Here, we determined the modulation pattern of the main key components of the UPP in the
gastrocnemius (GAS) of mice during the acute phase of lipopolysaccharide (LPS)-mediated endotoxemia (7.5 mg/kg – 8 h)
by measuring all three β1, β2 and β5 activites of the 20S and 26S proteasomes, the levels of steady state polyubiquitinated
proteins, mRNA levels of muscle ligases, as well as signaling pathways regulating the UPP. Another goal was to assess
the effects of administration of a specific proteasome inhibitor (epoxomicin, 0.5 mg/kg) on UPP response to sepsis.
Results: The acute phase of LPS-induced endotoxemia lowered GAS/body weight ratio and increased MuRF1 and
MAFbx mRNA concomitantly to an activation of the pathways known to regulate their expression. Unexpectedly, we
observed a decrease in all 20S and 26S proteasome activities measured in GAS, which might be related to oxidative
stress, as oxidized proteins (carbonyl levels) increase with LPS. While significantly inhibiting 20S and 26S proteasome β5
activities in heart and liver, epoxomicin did not lower proteasome activity in GAS. However, the increase in mRNA
expression of the muscle ligases MuRF1 and MAFbx were partially rescued without affecting the other investigated
signaling pathways. LPS also strongly activated autophagy, which could explain the observed GAS atrophy with
LPS-induced reduction of proteasome activity.
Conclusions: Our results highlight an opposite regulation of UPP in the early hours of LPS-induced muscle atrophy
by showing reduced proteasome activities and increased mRNA expression of muscle specific ligases. Furthermore,
our data do not support any preventive effect of epoxomicin in muscle atrophy due to acute cachexia since
proteasome activities are not further repressed.
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Skeletal muscle loss due to cachexia is clinically distinct
from other forms of muscle atrophy such as muscle disuse
or sarcopenia because it is always associated with an under-
lying disease and inflammation [1]. Endotoxic shock - or
sepsis - induces a severe and acute form of cachexia,
mainly due to an increase in protein degradation [2]. En-
dotoxic shock also induces hypotension, vascular damages
and inadequate tissue perfusion that lead to multiple
organ failure, including heart and liver failure [3]. The
pathogenesis of sepsis depends predominantly on lipo-
polysaccharide (LPS), which is a membrane component of
gram negative bacteria responsible for the endotoxic activ-
ity [4]. Therefore, administration of LPS to animals has
been extensively used to mimic sepsis [5].
The ubiquitin proteasome pathway (UPP) is a major
protein degradation pathway that is modulated during
sepsis. Briefly, ubiquitin-proteasome-dependent prote-
olysis is a two-step ATP-consuming process. In a first
step, the substrate is covalently bound to a polyubiquitin
chain through the sequential action of a triplet of en-
zymes. The second step implies the recognition, unfolding
and degradation of the polyubiquitinated substrate by a
multicatalytic complex, namely proteasome 26S. Polyubi-
quitin chain formation requires the sequential action of
three types of ubiquitin enzymes, respectively known as
ubiquitin-activating (E1), ubiquitin-conjugating (E2) and
ubiquitin-ligase (E3) enzymes. In catabolic conditions, the
most important regulations occur at the level of E3s,
which are numerous and responsible for the specificity
of protein-substrate recognition. In skeletal muscle
cells, upregulation of the tissue-specific E3 ligases
muscle ring finger 1 (MuRF1) and muscle atrophy F-
box (MAFbx) in response to LPS administration is now
well established [6,7].
Several forms of proteasomes exist in cells. The main
form, called the 26S proteasome, is composed of the 20S
core associated with one or two 19S particles that con-
tain subunits with ATPase activities. Another form is the
20S proteasome, which is ATP-independent but capable
of degrading oxidized proteins [8,9] as well as certain
non-ubiquitinated proteins [10,11], while the 26S form is
responsible for degrading polyubiquitinated proteins.
Proteolytically active sites are localized in the β1, β2 and
β5 subunits of the 20S proteasome. They are described
as caspase-like, trypsin-like and chymotrypsin-like activ-
ities, respectively, in accordance to the peptide bonds
that they cleave preferentially [12]. The β5 activity is be-
lieved to be the rate-limiting step for polypeptide degrad-
ation by the proteasome [12].
Several authors have suggested that proteasome could
be a potential therapeutic target for preventing the con-
sequences of sepsis [3,13,14]. Among the drugs designed
for that purpose (for review see [15]), epoxomicin is anatural product that was initially isolated from an Acti-
nomycetes strain for its antitumor properties. Unlike
most proteasome inhibitors, epoxomicin acts specifically
and does not inhibit nonproteasomal proteases. It irre-
versibly and covalently binds to the six 20S proteasome
catalytic subunits, with higher affinity for the β5 subunit
active site [16].
A few studies investigated the modulation of β5 prote-
asome activity in response to LPS administration [17-20].
However, we are unaware of any investigation characteriz-
ing the overall modulation pattern of the UPP in skeletal
muscle by measuring all 20S and 26S β1, β2 and β5 activ-
ities, mRNA of muscle ligases, the levels of steady state
polyubiquitinated proteins as well as signaling pathways
regulating UPP during LPS-mediated endotoxemia. Re-
cently, macroautophagy, here called autophagy, has been
implicated in LPS-mediated muscle atrophy [21-23]. Unc
51-like kinase 1 (ULK1) plays an essential role in the initi-
ation of autophagosome membrane formation. The subse-
quent elongation of this membrane is under the control of
several autophagy related-gene (ATG) proteins, including
microtubule-associated protein 1 light chain 3 (LC3).
Finally, the mature autophagosome, whose membrane
includes the lipidated form of LC3 (LC3II), fuses with
lysosomes containing hydrolases such as cathepsins.
This study was undertaken to determine how the UPP
is regulated in skeletal muscle during the acute phase of
LPS-mediated endotoxemia. Given that several authors
suggest that the proteasome itself could be a potential
therapeutic target for preventing sepsis consequences
[3,13,14], a second goal was to assess the effects of epox-
omicin administration on the UPP response to sepsis.
Our studies show that, during the acute phase of LPS-
induced endotoxemia, both MuRF1 and MAFbx ligases are
activated, together with the autophagy pathway. On the op-
posite, 26S and 20S proteasome activities are drastically re-
duced. This suggests that mechanisms of retro-feedback
could occur inside muscle cell to prevent any excessive pro-
tein breakdown.
Methods
Ethics statement
This study was carried out in strict accordance with the
Belgian Law of April 6, 2010 on the protection of labora-
tory animals. The protocol was approved by the Commit-
tee on the Ethics of Animal Experiments of the Université
catholique de Louvain (agreement number LA 1220548).
All efforts were made to minimize suffering.
Experiment protocol
Eighteen male C57BL6 mice (15 weeks old) were obtained
from the animal facility of the Université catholique de
Louvain. Animals were housed at 22°C on a 12 h dark-
light cycle with ad libitum access to food and water. The
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cages. Mice were randomly assigned either to control
(C, n = 6), LPS treatment (L, n = 6), or LPS plus epoxomi-
cin treatment (L + E, n = 6) groups. On the day of experi-
ment, mice were weighed and injected intraperitoneally
with vehicle (10% DMSO in saline solution, C and L
groups) or epoxomicin (Peptide Institute, Osaka, Japan),
0.5 mg/kg (L + E group). This dose was selected because it
was reported to inhibit the proteasome but was nontoxic
in vivo [16]. One hour after the first injection, animals
were injected with vehicle (saline solution, C group) or
LPS O127:B8 (Sigma Aldrich, Bornem, Belgium), 7.5 mg/kg
(L and L + E groups). Mice had free access to water. As
sepsis has been associated with anorexia [24], food was re-
moved in each group immediately after the first injection
to avoid any differences in food intake. Mice were anes-
thetized eight hours after LPS administration with a lethal
injection of a mix of ketamine (200 mg/kg) and xylazine
(20 mg/kg). This time point post-LPS was selected be-
cause it was previously shown to drastically increase
MuRF1 and MAFbx expression [7], which are considered
as accurate markers of the atrophy process [25]. Before
dissection, the depth of anesthesia was assessed by the ab-
sence of eyelid and pedal withdrawal reflexes. Animals
were weighed, and the right and left gastrocnemius mus-
cles as well as the heart and the liver were excised and
quickly frozen in liquid nitrogen. Muscles were subse-
quently weighed and samples were stored at -80°C until
further analysis.
Protein extraction for immunoblotting
Muscles were crushed with mortar and pestle in liquid
nitrogen. For each sample, one half of the powder was
kept at -80°C for RNA extraction. The other part was
homogenized in ice cold buffer containing 20 mM Tris,
pH 7.0, 270 mM sucrose, 5 mM EGTA, 1 mM EDTA,
1% Triton X-100, 1 mM sodium orthovanadate, 50 mM
sodium β-glycerophosphate, 5 mM sodium pyrophos-
phate, 50 mM sodium fluoride, 1 mM DTT (1,4-dithio-
threitol) and a protease inhibitor cocktail containing
1 mM EDTA (Roche Applied Science, Vilvoorde, Belgium).
Homogenates were centrifuged for 10 min at 10,000 g,
4°C. Supernatants were stored at -80°C. Protein content
was determined using the DC protein assay kit (Bio-Rad,
Nazareth Eke, Belgium) with bovine serum albumin (BSA)
as a standard.
SDS-PAGE and immunoblotting
Proteins (35 μg) were combined with Laemmli sample
buffer and warmed for 5 min at 95°C before loading on
gels. For protein carbonyl measurements, 5 μg protein
were derivatised with 2,4-dinitrophenyl hydrazine before
electrophoresis, as described by the protein oxidation kit
from Merck Millipore (Billerica, MA, USA). Samples wereseparated by SDS-PAGE for 1 h at a constant intensity
of 40 mA and transferred to PVDF membranes at 80 V
for 2 h. Membranes were blocked 1 h in 0.1% Tween 20
Tris-buffered saline (TBST) and 5% non-fat dry milk,
then incubated overnight at 4°C with one of the following
primary antibodies: Regulatory particle triple-A ATPase 1
(RPT1; Enzo, NY, USA), dinitrophenyl (Sigma Aldrich),
phospho-Akt Serine(Ser) 473, total Akt, phospho-factor 4E
binding protein 1 (4E-BP1) Threonine(Thr) 37/46, eukaryotic
elongation factor 2 (eEF2), phospho-forkhead box O3a Thr32
(FoxO3aThr32), inhibitor of nuclear factor of kappa B, alpha
IκBα, LC3b, LC3a, phospho-p38Thr180/Tyrosine (Tyr) 182,
phospho-ULK1Ser757, total ULK1 (Cell Signaling Technol-
ogy, Leiden, The Nederlands), p62 (Progen Biotechnik,
Heidelberg, Germany) or proteasome 20S α + β (Abcam,
Cambridge, UK). Membranes were washed three times
with TBST and incubated for 1 h at room temperature
with a secondary antibody conjugated to horseradish per-
oxidase (Sigma-Aldrich). Membranes were washed three
times before detection by chemiluminescence with ECL-
Plus Western blotting kit (Amersham Biosciences, Diegem,
Belgium). Films were scanned on an ImageScanner using
the Labscan software and bands were quantified with the
Image Master 1D Image Analysis Software (Amersham
Biosciences). Expression levels were normalized to eEF2,
whose expression was unaffected by treatments. Western
blots for RPT1 and protein carbonyls utilized Pierce Pico
plus ECL reagent, and quantification was carried out using
Quantity One Analysis Software (Bio-Rad, CA, USA) with
Ponceau S total protein staining of the lane as the
normalization control as previously described [26]. All the
bands detected in each lane by the anti-dinitrophenyl anti-
body (protein carbonyls) were quantified relative to total
protein staining (Ponceau S).
Protein extraction for enzymatic activities
Muscles were cut into small pieces with razor blades then
homogenized on ice with a Tenbroeck Tissue Grinder in
ice cold buffer containing 50 mM Tris, pH 7.5, 150 mM
NaCl, 5 mM MgCl2, 1 mM EDTA and 1 mM DTT.
Homogenates were centrifuged for 30 min at 10,000 g,
4°C. Supernatants were stored at -80°C. Protein con-
tent was determined using a Bradford protein assay kit
(Bio Rad) with BSA as a standard.
Enzymatic activity assays
Proteasomes
Enzymatic activities were determined fluorometrically
using specific substrates and inhibitors, as previously de-
scribed [27,28]. Each sample was assessed in quadruplicate
with two replicates containing inhibitors. For each assay,
all samples were run on the same plate. 26S proteasome
activities were determined by adding 100 μM Z-LLE-AMC
(Peptide Institute), LSTR-AMC (Bachem, CA, USA) or
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unit activities respectively. Assays using 25 μg of pro-
tein were carried out in a reaction buffer containing
50 mM Tris, pH7.5, 1 mM EDTA, 150 mM NaCl,
5 mM MgCl2, 0.5 mM DTT and 100 μM ATP, ± inhibi-
tor (40 μM Z-Pro-Nle-Asp-al (β1) (Biomol, PA, USA),
60 μM epoxomicin (β2) or 20 μM epoxomicin (β5)).
20S proteasome activities were determined similarly
but using different reaction buffers: β1 and β2 activities
were assayed in 25 mM HEPES, pH 7.5, 0.5 mM EDTA,
0.05% NP-40, 0.001% SDS. The β5 activity was assayed
in a similar buffer with the exception that the 0.05%
NP-40 and 0.001% SDS were replaced with 0.03% SDS
[27,29,30]. All 20S activity measurements were carried
out in the absence of ATP but in the presence of deter-
gent [28]. Fluorescence was monitored every 15 min
for 115 min on Fluoroskan Ascent FL (Thermo Scientific,
MA, USA) at an excitation and emission wavelength of
380 nm and 460 nm, respectively. Enzymatic activity was
calculated as the difference between fluorescence intensity
in the absence of inhibitor and fluorescence intensity in
the presence of inhibitor at 45 min. The fluorescence in-
tensity was linear over a range greater than 60 min.
Cathepsins
Cathepsin activities were assessed with 20 μg proteins
per well. Cathepsin B activity was assayed with 100 μM
Z-Arg-Arg-AMC (Biomol) in a reaction buffer contain-
ing 44 mM KH2PO4, pH 6.0, 6 mM Na2HPO4, 0.67 mM
EDTA, 1.35 mM Cysteine ± 10 μM cathepsin B Inhibitor
(Biomol). Cathepsin L activity was determined with
100 μM Z-Phe-Arg-AMC (Peptide Institute) in a buffer
containing 100 mM sodium acetate, pH 5.5, 1 mM EDTA,
1 mM DTT± 10 μM cathepsin L inhibitor I (Calbiochem,
Darmstadt, Germany). Fluorescence was also determined
at excitation and emission wavelengths of 380 nm and
460 nm as carried out for the proteasome assays.
Polyubiquitination ELISA Assay
ELISA assays were performed in high binding 96-well
microtiter plates (Santa Cruz Biotechnology, CA, USA).Table 1 Sequences of primers (5’-3’)
Gene Forward
Cphn CGTCTCCTTCGAGCTGTTTG
MAFbx CCATCAGGAGAAGTGGATCTATGTT
MuRF1 ACGACATCTTCCAGGCTGCGAATCC
Psmb1 CTTGATGAAGAAGGAAAGGGAG
Psmc2 GAAGGACGACAAGCCCATC
Rpl4 CGCAACATCCCTGGTATTACT
Tnf-α CAGACCCTCACACTCAGATCAWells were incubated with 1 μg of muscle lysate over-
night at 4°C, washed four times with PBST and excess
binding sites blocked with PBST containing 5% BSA.
Bound polyubiquitinated proteins were detected using
an anti-polyubiquitin antibody FK1 (Biomol), which does
not bind monoubiquitinated proteins or free ubiquitin.
Bound anti-polyubiquitin antibodies were detected using
anti-IgG/IgM conjugated with Horseradish peroxidase
(Sigma-Aldrich). After 1 h incubation with the secondary
conjugate, the plates were washed 5 times in PBST and in-
cubated at room temperature with Sureblue TMB substate
(KPL, MD, USA). After 5 min the color development
was stopped using 2.5 M sulphuric acid and the color
developed recorded with a Bio-Rad 680 microplate reader
at 450 nm. Controls using BSA and ubiquitin (negative)
and penta polyubiquitin chains (Biomol, positive control)
were used to validate the assay conditions.
RNA extraction and quantitative Real-Time PCR
Powdered muscles were homogenized in 1 ml Trizol® re-
agent (Invitrogen, Merelbeke, Belgium). RNA was isolated
according to the manufacturer’s instructions. RNA quality
and quantity were assessed by 1.5% agarose gel electro-
phoresis and Nanodrop® spectrophotometry. Reverse
transcription was performed from 1 μg RNA using the
iScript™cDNA Synthesis Kit from Bio-Rad, according to
the manufacturer’s instructions. Primers used for quan-
titative PCR are reported in Table 1. Experiments were
performed on MyIQ2 thermocycler, using the following
conditions: 3 min at 95°C, followed by 35 cycles of 30s
at 95°C, 30s at 60°C and 30s at 72°C. For each gene, all
samples were run in triplicate on the same plate. Each
reaction was processed in a 10 μl volume containing
4.8 μl IQ SybrGreen SuperMix (Bio-Rad), 0.1 μl of each
primer (100 nM final) and 5 μl cDNA of the appropriate
dilution. Melting curves were systematically assessed for
quality control. Relative mRNA expression levels were
normalized using the geNorm method described by
Vandesompele et al. [31]. For each sample, a normalization
factor was calculated, based on the geometric mean of the
two most stable genes out of the five tested (Cphn, Rpl4).Reverse NCBI accession number
CCACCCTGGCACATGAATC NM_008907.1
GCTTCCCCCAAAGTGCAGTA NM_026346.3
TCTCGTCTTCGTGTTCCTTGC NM_001039048.2
TGGTTGTCGAGCAGAGGC NM_011185.3
AGGTGCCAACCCAGTGTCAG NM_011188.3
TGTGCATGGGCAGGTTATAGT NM_024212.4
CCTTGTCCCTTGAAGAGAACC NM_013693.3
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Values are presented as means ± SEM. A one-way ANOVA
was conducted to evaluate statistical significance, except
for body weight on which a two-way repeated measures
ANOVA was applied. The Fisher LSD Method was
used for post-hoc tests. Statistical significance was set
at P < 0.05.
Results
In this study, we choose an acute model of LPS adminis-
tration to investigate the modulation of the various com-
ponents of the UPP as well as the regulatory pathways
within the GAS. Due to this acute model, there was no
difference between groups in body weight loss, which is
likely attributed to food deprivation only (Figure 1A).
GAS weight was not significantly modified (Figure 1B).
Nevertheless, the GAS weight/body weight ratio (Figure 1C)
was 3.05 ± 0.73% lower (P = 0.027) in the L group, com-
pared to the C group.
The timing and the dose of LPS selected are known to
drastically increase MuRF1 and MAFbx expression [7],
which are considered to be master regulators of UPP-
related proteolysis in skeletal muscle [25]. In agreement
with the literature, MuRF1 and MAFbx mRNA levels
were increased after LPS administration by 11.93 ± 0.66
fold (P < 0.001) and 2.87 ± 0.26 fold (P < 0.001), respectively
(Figure 2A,B). A smaller increase was observed for the
proteasome subunits Psmb1 (1.46 ± 0.12 fold, P = 0.006)
and Psmc2 (1.17 ± 0.03 fold, P = 0.003) (Figure 2C,D).
Epoxomicin administered 1 h before LPS repressed the
increase in MuRF1 by 24% (P = 0.044), MAFbx by 58%
(P = 0.010) and Psmc2 by 74% (P = 0.018) (Figure 2A,B,D).
Amongst the transcription factors implicated in the
control of atrogene expression, members of the forkhead
box O (FoxO) family, such as FoxO3a seem to be master
regulators [32]. In atrophying muscles, Akt is known to
be dephosphorylated, leading to subsequent dephosphor-
ylation of FoxO3a which can in turn translocate into the
nucleus and activate transcription of target genes [33].
With LPS, Akt and FoxO3a were dephosphorylated by
66 ± 10% (P < 0.001) and 60 ± 9% (P = 0.002), respectivelyFigure 1 Animal characteristics. Body weight (A), GAS weight (B) and ra
administration of LPS 7.5 mg/kg with or without epoxomicin 0.5 mg/kg tre
control (C), LPS (L) and LPS + epoxomicin (L + E) treated animals. Values are
compared with C.(Figure 3A,C). As total Akt protein level was constant
(Figure 3B), this supports a nuclear translocation of
FoxO3a that is dependent on the inactivation of Akt.
The latter also controls protein synthesis through the
activation of mammalian target of rapamycin (mTOR).
We measured the phosphorylation state of a down-
stream target of mTOR, namely 4E-BP1, which was low-
ered by 53 ± 11% (P = 0.001) in the L group (Figure 3D).
Treating with epoxomicin had no further effect on the
phosphorylation states of Akt, FoxO3a and 4E-BP1 in
comparison with LPS treatment alone (Figure 3).
LPS is a ligand for toll-like receptor 4 (TLR4) [34]. This
membrane receptor is known to activate p38 mitogen-
activated protein kinase (MAPK) [21] and nuclear fac-
tor kappa B (NF-κB) [35], two pathways implicated in
the regulation of atrogene transcription [36-38]. With
LPS, p38 phosphorylation increased by 6.78 ± 1.16 fold
(P < 0.001), the NF-κB target gene tumor necrosis factor
alpha (Tnf-α) increased by 4.88 ± 0.78 fold (P < 0.001)
and the protein level of IκBα was decreased by 39 ± 7%
(P = 0.013) (Figure 4). Again, adding epoxomicin did not
have any further effect on phospho-p38, Tnf-α or IκBα
when compared to LPS alone (Figure 4).
Proteasome 20S and 26S enzymatic activities are shown
in Figure 5. Epoximicin is a selective proteasome inhibitor,
which shows the highest affinity for β5. Nevertheless, in
GAS muscle, the β5 activity was not significantly lower in
the L + E group compared to the L group (Figure 5A,B).
Because of this unexpected result, we measured prote-
asome activities in heart and liver. As expected, the β5
activities of the 20S and 26S proteasome were lower in
the L + E group compared to the L group in liver (-59%
and -52%, respectively) and heart (-36% and -35%, respect-
ively; Figure 5C-F).
Since LPS is known for inducing muscle atrophy [39],
we expected an increase in proteasome activity after LPS
injection. However, the results showed a general decrease
in proteasome activities 8 hours after LPS injection. In
GAS muscle, LPS induced a decrease in all proteasome
activities (Figure 5A,B): -43%, -38% and -29% for the 20S
β1, β2 and β5 activities respectively, and -30%, -22% andtio of GAS weight on body weight (BW) (C) of mice 8 hours after
atment. Weight of GAS was measured in left and right muscles of
means ± SEM. Panel A: *** p < 0.001, PRE vs. POST; Panel C: * p < 0.05,
Figure 2 Transcriptional regulation of UPP. mRNA expression levels of MuRF1 (A), MAFbx (B), Psmb1 (C) and Psmc2 (D) in the GAS of mice
8 hours after administration of LPS 7.5 mg/kg with or without epoxomicin 0.5 mg/kg treatment (L + E and L, respectively). Values are means ± SEM.
* p < 0.05, ** p < 0.01, *** p < 0.001 compared with control (C); # p < 0.05 compared with LPS (L).
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heart, 20S β1 (-55%), 20S β2 (-45%) and 26S β5 (-23%)
proteasome activities were lower in the L group in com-
parison with the C group (Figure 5C,D). In liver, the
20S β5 and 26S β5 activities were also decreased (-29%
and -30%, respectively; Figure 5E,F). The β2 activity in
the liver was not measured because this tissue contains
significant non-proteasomal trypsin-like protease(s) that
readily cleaves the proteasome substrate, preventing highly
accurate proteasomal activity measurements [40].
The levels of steady state polyubiquitinated proteins
are presented in Figure 6. LPS did not significantly affect
polyubiquitination although there was a trend toward
increased polyubiquitination in liver (1.28 ± 0.10 fold,
P = 0.077, Figure 6C). Epoxomicin decreased polyubi-
quitination by 23% in GAS muscle (L vs. L + E, P = 0.051,
Figure 6A) and conversely increased it by 41% in liver
(L vs. L + E, P = 0.004, Figure 6C), the latter being consist-
ent with proteasome β5 inhibition.
RPT’s (proteasome regulatory particles) are ATPases
that are located in the 19S proteasome regulator base
and which are targets for carbonylation [41]. Figure 7
shows that LPS administration increased carbonyl levels
by 38% (P = 0.022, Figure 7A) while the 19S ATPase RPT1
protein levels decreased by 55% (P < 0.001, Figure 7B),
both in GAS. When epoxomicin was administrated to LPS
animals, the increase in carbonyl levels was completelyrescued (L vs. L + E, P = 0.033, Figure 7A) while the de-
crease in RPT1 was rescued by 44% (L vs. L + E, P = 0.027,
Figure 7B). Alternatively, protein levels of proteasome 20S
remained unchanged (Figure 7C).
Accumulation of LC3bII has been best correlated to
autophagosome accumulation and used as a positive marker
for increased autophagosome presence [42], while determin-
ation of the ratio of LC3II on the non-lipidated form
(LC3I) has been considered a reliable assay for autopha-
gosome synthesis [43]. In GAS, LC3bII and the LC3aII/
LC3aI ratio were increased after LPS injection by 13.24 ±
3.09 fold (P = 0.005, Figure 8A) and 8.04 ± 14.41 (P < 0.001,
Figure 8B) fold respectively. It was not possible to calculate
an LC3bII/LC3bI ratio as the antibody (catalog number
3868, Cell Signaling Technology) that we used has a stron-
ger reactivity with the LC3bII form than with the LC3bI
form [21]. The LPS-induced changes in LC3 were not al-
tered when epoxomicin was administered. Autophagosome
accumulation inside the cell can be due to defects in
lysosomal degradation that can be assessed via the accu-
mulation of p62 [44,45], which is a protein cargo involved
in degradation of ubiquitinated protein aggregates through
autophagy and which is known to be degraded together
with autophagosome content. In GAS, p62 protein levels
were lowered by 23% after LPS injection (P = 0.058,
Figure 8C). The autophagy inductor ULK1 is repressed
when phosphorylated at Ser757 by mTOR. In GAS,
Figure 3 Phosphorylation state of UPP regulatory proteins. Phosphorylation state of AktSer473 (A), protein level of Akt (B), phosphorylation
states FoxO3aThr32 (C) and 4E-BP1Thr37/46 (D) in the GAS of mice 8 hours after administration of LPS 7.5 mg/kg with or without epoxomicin
0.5 mg/kg treatment. Values are means ± SEM. ** p < 0.01, *** p < 0.001 compared with control (C). §: Western blot analyses for 4E-BP1 Thr37/46 and
FoxO3aThr32 originate from the same gel and the representative western blot comes from the same set of samples. Therefore, loading control
eEF2 is the same.
Figure 4 LPS signaling. Phosphorylation state of p38Thr180/Tyr182 (A), protein expression level of IκBα (B) and mRNA expression level of Tnf-α in
the GAS of mice 8 hours after administration of LPS 7.5 mg/kg with or without epoxomicin 0.5 mg/kg treatment. Values are means ± SEM. *
p < 0.05, ** p < 0.01, *** p < 0.001 compared with control (C).
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Figure 5 Effect of LPS on proteasome activities in gastrocnemius, heart and liver. Proteasome 20S (A, C, E) and 26S (B, D, F) enzymatic
activities in the GAS (A, B), heart (C, D) and liver (E, F) of mice 8 hours after administration of LPS 7.5 mg/kg with or without epoxomicin
0.5 mg/kg treatment. Values are means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with control (C); ## p < 0.01, ### p < 0.001 compared
with LPS (L).
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http://www.biomedcentral.com/1471-2474/15/166phosphorylation of ULK1 at Ser757 was lowered by
69% after LPS injection (P < 0.001, Figure 8D), while
the total form of the kinase was unaffected by treatments
(Figure 8E). Cathepsin B and L lysosomal enzymatic activ-
ities were not affected by LPS administration or treatment
with expomicin prior to LPS (Figure 8F and G).
Discussion
The main finding of the present study is the unexpected
attenuation of all proteasome activities in skeletal muscle
during the early hours of LPS-induced endotoxemia.
The same pattern of regulation was also observed in car-
diac tissue while only β5 activities were decreased in liver.
As detailed in the methods, enzymatic activities wereFigure 6 Levels of steady state polyubiquitinated proteins. (A), heart (
with or without epoxomicin 0.5 mg/kg treatment. Values are means ± SEM
## p < 0.01, compared with LPS (L).determined fluorometrically using specific substrates and
inhibitors, following a validated protocol [28] that was
previously used to show increase in proteasome activities
following denervation-induced muscle atrophy [27].
The regulation of proteasome activity in skeletal muscle
in response to LPS administration was investigated by pre-
vious in vivo studies. An increased β5 activity of rat soleus
and extensor digitorum longus was observed 24 hours after
LPS for doses ranging from 1 to 12 mg/kg [17,20] and
similar results were reported for the diaphragm of rat
48 hours after LPS administration [18]. Intravenous ad-
ministration of a low dose of endotoxin to human reduced
protein degradation without changing proteasome β5
activity after 3 hours [19]. Taken together, these resultsB) and liver (C) of mice 8 hours after administration of LPS 7.5 mg/kg
. * p < 0.05, *** p < 0.001 compared with control (C); # p < 0.05,
Figure 7 Markers of LPS-induced oxidative stress. Effect of LPS on protein carbonyl expression level (A), RPT1 protein expression level (B) and
proteasome 20S α + β protein expression level (C) in the GAS of mice 8 hours after administration of LPS 7.5 mg/kg with or without epoxomicin
0.5 mg/kg treatment. Samples of each blot were ran on the same gel. Values are means ± SEM. * p < 0.05, *** p < 0.001 compared with control
(C); # p < 0.05 compared with LPS (L).
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well as the delay between LPS injection and muscle col-
lection might explain the discrepancy between our re-
sults and those previously reported in the literature.
Therefore, the choice of the delay between LPS injection
and the animal sacrifice is critical. We choose a delay of
8 hours because this delay was known to drastically in-
crease MuRF1 and MAFbx expression [7], which are
considered to be master regulators of UPP-related pro-
teolysis in skeletal muscle [25].
The mechanisms responsible for the decrease in prote-
asome activities in the early hours after LPS injection re-
main unclear. This decrease was not related to changes
in proteasome 20S abundance, as the various 20S sub-
units, including β1, β5 and β5i were not affected. Never-
theless, these subunits must be assembled to fulfill their
degradation function. Hence, it is possible that prote-
asome assembly was altered by acute LPS administration
without showing any changes in protein subunit expres-
sion levels. Further research should be conducted to in-
vestigate that hypothesis. Alternatively, proteasome 20S
activity is regulated through association with regulatory
particles, the best described of them being the prote-
asome 19S. A reduction in proteasome activities has
been proposed as a mechanism for sparing energy since
less ATP would be consumed by proteasome 19S [46].
The reduced level of RPT1 ATPase due to sepsis is an
element in favor of that hypothesis, which is also sup-
ported by the close association between endotoxemia
and a decreased ability to generate ATP through oxida-
tive metabolism during acute phase of sepsis [47].
Proteasome assays measure the catalytic activity of the
20S (ATP-independent) or 26S forms (ATP-dependent)
for a given substrate concentration. Our results suggest the
presence of an inhibitory process, which represses all prote-
asome activities in response to acute LPS administration.Oxidative stress could be the inhibitory link between LPS
and proteasome inhibition. Proteasomal degradation is
known to be repressed in vitro through carbonylation of
ATPase subunits of proteasome 19S [41]. 19S ATPases –
also known as Rpts - are located in the base of the 19S
particle. Their functions are to bind substrates selectively,
to open the gate formed by the α-ring of the 20S, to un-
fold substrates and to allow substrate translocation inside
the proteolytic room of the 20S. For all these reasons,
their association with the 20S proteasome stimulates
proteasomal protein degradation [48]. In this study, we
showed that the level of protein carbonyls increased
with LPS administration and was associated with a large
decrease in RPT1 protein level. This coincides with the
decrease in proteasome 20S activities. As carbonyls can
be degraded independently of ATP directly by the 20S,
this supports a role of oxidative stress in LPS-induced
proteasome inhibition.
Transcripts coding for proteasome subunits PSMB1
and PSMC2 were increased 8 hours after LPS administra-
tion. This suggests that a feed-back mechanism occurs to
restore/increase the level of proteasome 19S/20S subunits,
which is consistent with the later increase in proteasome
activity reported by other investigators [17,18,20].
Even though the catalytic activities of the proteasome
were decreased, the total protein amount was likely lower
after LPS administration [6]. Indeed, the GAS/body weight
ratio was decreased supporting the idea that atrophy was
already occurring at the time of the sacrifice, i.e. 8 hours
after LPS injection. The decrease in the assayed prote-
asome activities does not necessary implicate an in vivo
repression of the overall UPP activity. A higher amount
of substrate available for proteasome degradation could
increase the rate of protein breakdown through the pro-
teasome. Although the amount of protein available for
20S proteasome degradation is unknown, the lack of any
Figure 8 Effect of LPS on autophagy protein markers and lysosomal enzymes. Protein expression level of LC3bII (A), protein expression
ratio of LC3aII on LC3aI (B), protein expression level of p62 (C), phosphorylation state of ULK1Ser757 (D), protein expression level of ULK1 (E),
enzymatic activities of Cathepsin B (F) and Cathepsin L (G) in the GAS of mice 8 hours after administration of LPS 7.5 mg/kg with or without
epoxomicin 0.5 mg/kg treatment. Values are means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with control (C).
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proteins after LPS injection argues against a substrate-
dependent regulation of the 26S form. It is possible that
although the proteasome activities are reduced by LPS,
they remain high enough to ensure the removal of ubi-
quinated substrates available for degradation in vivo.
Taken together, our results clearly show that UPP com-
ponents are not necessarily regulated in the same way in
response to a catabolic signal such as LPS and suggest
that mechanisms of retro-feedback could occur to pre-
vent any excessive protein breakdown.
Moreover, increased activity of other degradation pathways
like autophagy might also explain the apparent discrepancybetween the reduced proteasome activities and the de-
crease in muscle weight. Indeed, we observed changes in
autophagy induction marker phospho-ULK1Ser757, autop-
hagosome presence marker LC3bII and autophagosome
formation marker LC3aII/LC3aI as well as autophagic flux
marker p62, which are all consistent with a strong activa-
tion of protein degradation through the autophagy-
lysosomal pathway in response to LPS injection, even if
cathepsin L and cathepsin B activities were not affected.
A decrease in protein synthesis was observed by Lang
et al. 4 hours after LPS administration and was associ-
ated to a massive dephosphorylation of 4E-BP1 [6]. Our
results also show that LPS induces a dephosphorylation
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http://www.biomedcentral.com/1471-2474/15/166of 4E-BP1 8 hours after LPS injection and reinforce the
arguments for a negative protein balance.
Muscle atrophy is a major health matter. Development
of therapeutic strategies aiming to counteract muscle
loss is crucial. When physical exercise is infeasible and
when nutritional strategies are ineffective, the use of
pharmacological agents is the only way to prevent muscle
atrophy. As UPP is one of the two main pathways respon-
sible for the degradation of the bulk of the proteins in skel-
etal muscle, proteasome inhibitor administration seems an
interesting approach to prevent muscle wasting, especially
knowing that a proteasome inhibitor has been approved
for hematological malignancy therapy. Additionally, ad-
ministration of proteasome inhibitors in rodents reduced
plasma cytokine increase and prolonged survival in septic
shock, which makes them attractive therapeutic agents
[13,14]. Epoxomicin was chosen because of its specific in-
hibition on proteasome activity and its high affinity for the
β5 subunit [16], which is believed to be the rate limiting
step for proteasomal degradation [12]. Our results showed
that in vivo administration of epoxomicin was effective for
inhibiting 20S and 26S proteasome β5 activities in the hep-
atic and cardiac muscle cells whereas this inhibition was
much weaker and not significant in the skeletal muscle
cell. The unexpected inhibition of proteasome activity due
to acute LPS administration made it unlikely that prote-
asome inhibition would have an effect on muscle atrophy
under the conditions investigated. A lower sensitivity to
proteasome inhibitors inherent to skeletal muscle cells
could be due to tissue specific reactivity. Protein degrad-
ation was reported to be less sensitive to proteasome in-
hibitors in isolated skeletal muscles than in cultured cells
possibly due to slower up-take or a faster degradation in
skeletal muscle than in other tissues [49]. Alternatively,
epoxomicin was administered by intraperitoneal injection,
a commonly used route for small laboratory animals.
Drugs administered intraperitoneally are primarily absorbed
through the portal circulation. Therefore, they must pass
through the liver before reaching other organs [50]. The
liver plays numerous important physiological roles, in-
cluding detoxification. It is therefore conceivable that
epoxomicin was partly removed before reaching the infer-
ior vena cava and being distributed to other tissues. The
fact that proteasome activity was strongly inhibited in the
liver and to a lesser extent in the heart is an element in
favor of that hypothesis. Intravenous and subcutaneous in-
jections are two approved routes of administration of the
proteasome inhibitor bortezomib in humans and inhibit
20S proteasome activity to the same extent [51]. Future
animal studies could use one of these two routes to be
able to correlate the results with human studies.
The results of the present study confirm that the ex-
pressions of muscle specific ligases MuRF1 and MAFbx
are repressed by proteasome inhibitors. In a previousstudy, we showed that the administration of another less
specific proteasome inhibitor MG132 reduced muscle at-
rophy caused by a 6-day hindlimb suspension [52]. This
was associated with a repression of the increase of
MuRF1 and MAFbx. Another study reported similar
results in response to a 7-day hindlimb immobilization
protocol [53]. Among signaling pathways regulating muscle
ligase mRNA expression, NF-κB is a transcription factor
potentially repressed by proteasome inhibitor. Under atro-
phy signal, the inhibitory protein of NF-κB, IκBα becomes
phosphorylated and so is marked for ubiquitination and
subsequent proteasomal degradation. Therefore, prote-
asome inhibitors could prevent IκBα degradation and
thereby NF-κB activation as well as subsequent increase in
ligase mRNA. In our previous study, IκBα was unchanged
at the end of the 6-day hindlimb suspension protocol.
However, this does not preclude an activation of NF-κB as
IκBα may have been degraded at the onset of the unload-
ing and returned to a basal level at the time of sample col-
lection, while MuRF1 and MAFbx remained elevated.
Caron et al. also showed a repression of the increase in
MuRF1 and MAFbx in immobilized animals treated with
MG-132 which was associated to a reduced increase of
the Tnf-α, interleukin-6 and interleukin-1 cytokines, which
are known to be regulated by NF-κB [53]. The activation
of the NF-κB pathway assessed in the present study by a
decreased IκBα level and an increased Tnf-α in response
to LPS, was not altered by epoxomicin administration.
This is consistent with the fact that proteasome β5 activity
was not inhibited in skeletal muscle.
Circulating pro-inflammatory cytokines – especially
TNF-α - can regulate MuRF1 and MAFbx through p38
activation. Therefore, another explanation for a de-
crease in muscle ligase mRNA expression could be an
anti-inflammatory effect of epoxomicin. However, the
lack of change in Tnf-α and in p38 phosphorylation
state after epoxomicin injection argues against this
hypothesis.
Among signaling pathways regulating catabolism, the
phosphoinositide-3-kinase (PI3K)/Akt/FoxO3 pathway
coordinately regulates UPP and autophagy [54]. Studies
dealing with LPS provide controversial results on the acti-
vation of this pathway. While LPS increases Akt phosphor-
ylation state in C2C12 cell culture [6], LPS administration
in vivo seems to repress Akt [21,39]. Here we show a dras-
tic dephosphorylation of both Akt and FoxO3 with LPS
administration, which was not reversed by epoxomicin
treatment.
Muscle ligase expression can also be regulated by oxi-
dative stress [55]. In the present study, protein oxidation
was rescued in LPS animals following epoxomicin ad-
ministration suggesting indirect anti-oxidant properties
for epoxomicin, which could explain the lower increase
in MuRF1 and MAFbx.
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receiving epoxomicin only. Based on available literature
we hypothesized an increase in proteasome activity after
LPS injection. The number of groups (3) was chosen
with the goal of studying the protective effect of epoxo-
micin. Due to the LPS-induced decrease in proteasome
activities, it is difficult to interpret if epoxomicin was in-
effective in muscle because of tissue insensitivity or if
epoxomicin is not useful at this time-point because pro-
teasome activities are lowered. To investigate the various
components of UPP and the regulatory signaling path-
ways, we chose an early time-point for sample collection.
Therefore, the experimental design used in this study
does not allow an investigation of any potential inter-
action between LPS and epoxomicin.Conclusions
In conclusion, the results of the present study show that
proteasome activities are reduced in mice skeletal muscle
during the acute phase of LPS-mediated endotoxemia
whereas mRNA coding for atrogenes is increased. MuRF1,
MAFbx and RPT1 are partially rescued when epoxomicin
injection precedes LPS administration. Nevertheless, our
data does not support the idea that epoxomicin could be
useful for preventing muscle wasting in the early hours of
sepsis since muscle mass does not seem to be protected
and proteasome activities are not further reduced.
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